Now recruiting patients with ulcers for a study supported by NHS England

Contact us if your ulcer is less than 6 weeks old and you live in South-East England

Goal is to determine patient and economic benefits of using Acapsil as first-line treatment at GP-surgeries. Acapsil is already approved and available for sale over-the-counter.

To participate, your venous leg ulcers or diabetic foot ulcers must be less than 6 weeks old.
You must live in Hampshire, East Dorset, West Surrey, Berkshire or the western part of West Sussex.

Goal is to determine patient and economic benefits of using Acapsil as first-line treatment at GP-surgeries. Acapsil is already approved and available for sale over-the-counter.

To participate, your venous leg ulcers or diabetic foot ulcers must be less than 6 weeks old.
You must live in Hampshire, East Dorset, West Surrey, Berkshire or the western part of West Sussex.

60% quicker
than antibiotics

at removing infection

at removing infection

at removing infection

Passive Immunotherapy

Acting via the skin microbiome

Acting via the skin microbiome

Acting via the skin microbiome

Removes pain,
smell and discharge

by efficiently removing the infection

by efficiently removing the infection

by efficiently removing the infection

Less Scarring

"Where I have used Acapsil the scarring is flat, whereas the older scars are hypertrophic." ST

"Where I have used Acapsil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic." ST

"Where I have used Acapsil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic." ST

"Acapsil changed my life."

"From 4 weeks of absolute hell - to being pain-free, getting a full night's sleep and back to normal at work."

"From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work - to being pain-free, getting a full night's sleep and back to normal at work."

"From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work - to being pain-free, getting a full night's sleep and back to normal at work."

NH ( patient)

NH ( patient)

NH ( patient)

Did you know:
killing the microbes in your wound makes YOU resistant!

MPPT removes infection without killing

MPPT removes infection without killing

MPPT removes infection without killing

69.5% Savings

Cost-effectiveness determined in NHS Clinical Audit

Cost-effectiveness determined in NHS Clinical Audit

Cost-effectiveness determined in NHS Clinical Audit

Hypoallergenic

Only natural ingredients

Only natural ingredients

Only natural ingredients

FDA Executive Review:

Antibiotic and antiseptic dressings do not improve wound infections or wound healing.

Antibiotic and antiseptic dressings do not improve wound infections or wound healing.

Antibiotic and antiseptic dressings do not improve wound infections or wound healing.

US FDA 2016

US FDA 2016

US FDA 2016

In connection with publication on MPPT, the

In connection with publication on MPPT, the

In connection with publication on MPPT, the

Chair of WHO Anti-Microbial-Resistance group said:

“AMR is an escalating global threat. We need alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria.”

“AMR is an escalating global threat. We need alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria.”

“AMR is an escalating global threat. We need alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria.”

“For me, this Acapsil open air method is a no brainer. It is easier, no fuss, and obviously cheaper than these expensive dressings.”

VH (patient)

VH (patient)

VH (patient)

previous arrow
next arrow
Slider
See publication in WOUNDS here.

Objective

The purpose of the study was to evaluate the wound healing effects of MPPT and to compare it to antibiotics and antiseptics. The study included a wide range of wounds and ulcers, which were severely colonised to infected. The comparators were the topical antibiotic Gentaxane, which is a combination of an absorbing powder and the antibiotic gentamicine, and the antiseptic Ioddicerin, which is a combination of iodine and DMSO, where the latter is used to improve tissue penetration.

Method
  • The study included a total of 266 patients with primarily trophic ulcers caused by venous insufficiency of lower extremities and diabetes, carbuncles, phlegmons, infected heat burns of degree III – IV, and infiltrations of postoperative wounds.
  • MPPT, a topical antibiotic (gentamicin) and an antiseptic (iodine) were applied once daily to the wound surface and the edges until the wound was clean, i.e. free from necrosis, pus and fibrinogenous thickenings.
  • For each patient, it was recorded when the wound reached a clean wound, onset of granulation and onset of epithelialisation as well as the number of bed-days from start of application until the patient was able to leave the hospital to continue treatment at a walk-in clinic.
  • For a subgroup of patients with abscesses, carbuncles and post-operative infected wounds, the wound surface area was measured at 4 time points during the first 10 days after start of application.
Results
The number of days (mean±SD) to reaching a clean wound (free of necrosis, pus and infection) was 3.0±0.9 for MPPT (n=88) compared to 7.0±1.2 and 8.0±1.1 for antibiotic (gentamicin) (n=90) and antiseptic (iodine) (n=88), respectively. MPPT thus reduced the time to reaching a clean wound by 57% and 62%, respectively. Comparison of MPPT to antibiotic and antiseptic to reach start of granulation. Days to Onset of Granulation were for MPPT, antibiotic, and antiseptic: 4.5±0.8; 9.2±1.4; and 10.3±1.5 days, respectively Days to onset of epithelialisation for MPPT, antibiotic (gentamicin) and antiseptic (iodine). Days to Onset of Epithelialisation were: 7.8±1.1; 14.1±1.9; and 16.4±2.7 days, respectively
Days (mean±SD) to reaching the three Wound Healing Stages in patients following application of MPPT (n=88), antibiotic (n=90), or antiseptic (n=88).
acapsil-density-clean Scatter-plot of Days to onset of granulation for MPPT, antibiotic (gentamicin) and antiseptic (iodine). Scatter-plot of Days to onset of epithelialisation for MPPT, antibiotic (gentamicin) and antiseptic (iodine).
Density plots for all 266 patients in the study. The graphs show days to reach the clean
wound stage, onset of granulation and onset of epithelialisation and bed-days following application of MPPT (n=88), antibiotic (n=90) or antiseptic (n=88).

For the entire patient group, the number of days (mean±SD) to reaching a clean wound was 3.0±0.9 for MPPT (n=88) compared to 7.0±1.2 and 8.0±1.1 for antibiotic (n=90) and antiseptic (n=88), respectively. MPPT thus reduced the time to reaching a clean wound by 57% and 62%, respectively. The products were used until reaching a clean wound and days to clean wound therefore also reflect number of days of application. Days to Onset of Granulation were for MPPT, antibiotic, and antiseptic: 4.5±0.8; 9.2±1.4; and 10.3±1.5 days, respectively, and days to Onset of Epithelialisation were: 7.8±1.1; 14.1±1.9; and 16.4±2.7 days, respectively. A sub-group analysis of patients with diabetic foot and venous leg ulcers found that these demonstrated the same pattern of healing.

Percent reduction in hospital bed-days by MPPT compared to topical antibiotic and antiseptic (iodine).
Percent reduction in hospitalisation-days by MPPT compared to topical antibiotic and iodine.

The number of hospitalisation-days was 14.6±5.6 for MPPT, 21.0±10.7 for antibiotic and 24.0±7.9 for antiseptic (p<0.001). Compared to the antibiotic, patients receiving MPPT had a 31% reduction in number of hospitalisation-days and compared to the antiseptic 39%.

For the subgroup of patients with carbuncles, abscesses and post-operative infected wounds (n=30 per group) the wound surface area was at Day 1 the same in the three groups, but at Days 5, 7 and 10, the MPPT group had significantly smaller areas than the other groups and reached wound closure significantly faster. There were no significant differences between the antibiotic and the antiseptic.
Wound surface (sq. cm) for Days 1 to 10 following start of application. N=30 per group. Each group included 30 patients and the distribution of wound types was 80% carbuncles, abscesses, and cysts and 20% infected wounds for all three groups.

For the subgroup of patients with carbuncles, abscesses and post-operative infected wounds (n=30 per group) the wound surface area was at Day 1 the same in the three groups, but at Days 5, 7 and 10, the MPPT group had significantly smaller areas than the other groups and reached wound closure significantly faster. There were no significant differences between the antibiotic and the antiseptic.

MPPT did not cause any severe adverse reactions, irritation, bleeding or contact sensitivity.

Discussion

Thomas (2006) found that the critical aspect of the wound healing process for wounds demonstrating delayed healing is to reach the state of a clean wound bed, i.e. free from critical colonisation and inflammation. Once this state has been reached, the healing process will proceed and the time to wound closure is more or less constant.

Time lines for healing. MPPT, compared to a topical antibiotic, reduced the time to a clean wound by 60% and the time from a clean wound to onset of granulation and epithelialisation by 32%. In contrast, the time from onset of epithelialisation to the patient being able to leave the hospital was constant.
Duration of wound healing phases for each of the 3 groups and percent reduction by MPPT compared to a topical antibiotic .

The present study found that MPPT, compared to a topical antibiotic, reduced the time to a clean wound by 60% and the time from a clean wound to onset of granulation and epithelialisation by 32%. In contrast, the time from onset of epithelialisation to the patient being able to leave the hospital was constant. These data support the theory by Thomas (2006) that reducing the time to a clean wound has a substantial impact on the overall wound healing process, but the data also indicate that the transition from the inflammatory to the proliferative wound healing phase is less distinct and that MPPT also accelerates at least the early stages of the proliferative phase. The study did not follow the individual wounds until closure and the actual duration of the complete proliferative phase is therefore not known, but MPPT reduced the time to onset of epithelialisation by approximately 7 days compared to the antibiotic and the MPPT patients left the hospital 7 days earlier than patients receiving a topical antibiotic, so the data indicate that MPPT mainly achieved its effect by accelerating the transition from the inflammatory phase into the proliferative phase.

Conclusion

MPPT reduced the time to achieving a clean wound by 60% compared to a topical antibiotic (gentamicin) and the antiseptic iodine. Furthermore, MPPT reduced the number of hospitalisation-days by 31% and accelerated the rate of wound closure. Together, these findings demonstrate that MPPT assists the wound healing process and is safe to use.

Close Menu
Close Panel